✦ LIBER ✦

Is There a Cardiovascular Rationale for the Use of Combined Vasopressin V1a/V2 Receptor Antagonists?

✍ Scribed by Steven R. Goldsmith

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vascular Effects of RWJ-676070, a Select

✍ Coltamai, L; Bucher, M; Maillard, MP; Shukla, U; Bohidar, N; Haskell, L; Bertels 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 322 KB

Properties of a new radioiodinated antag

✍ Youssef Ala; Denis Morin; Eve Mahé; Nathalie Cotte; Bernard Mouillac; Serge Jard 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 396 KB

Pharmacological characterization of RWJ-

✍ Joseph W. Gunnet; Pamela Wines; Min Xiang; Philip Rybczynski; Patricia Andrade-G 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 905 KB

Pharmacokinetic and pharmacodynamic effe

✍ M. Burnier; A. F. Fricker; D. Hayoz; J. Nussberger; H. R. Brunner 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 110 KB

EFFECT OF CONIVAPTAN, A COMBINED VASOPRE

✍ TAKEYUKI YATSU; TOSHIYUKI KUSAYAMA; YUICHI TOMURA; YUKINORI ARAI; MOTONORI AOKI; 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 311 KB

Pharmacological characterization of YM47

✍ Junko Tsukada; Atsuo Tahara; Yuichi Tomura; Koh-ichi Wada; Toshiyuki Kusayama; N 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 354 KB